#394 ‒ Sleep pharmacology: the role of medications in healthy sleep, the promise of emerging therapies, and the evidence for common sleep supplements

What It Covers

Peter Attia maps the full landscape of sleep pharmacology, covering four root causes of poor sleep, then systematically evaluating benzodiazepines, z-drugs, DORAs, melatonin, trazodone, antihistamines, and supplements including glycine, magnesium, and ashwagandha against those specific mechanisms.

Key Questions Answered

• •Matching medication to mechanism: Sleep problems fall into four distinct categories — sleep pressure deficits, circadian misalignment, hyperarousal, and poor sleep architecture — and applying the wrong treatment to the wrong problem causes tolerance, dependence, or worsened sleep. Identifying which system is broken before selecting any tool, behavioral or pharmacological, is the critical first step.
• •DORAs and Alzheimer's prevention: Dual orexin receptor antagonists like suvorexant (Belsomra) at 20mg reduced cerebrospinal fluid amyloid-beta by roughly 20% in a 2023 human trial of 38 adults. Unlike Ambien, DORAs preserve slow-wave sleep and the glymphatic waste-clearance system that removes tau and amyloid-beta during deep sleep, making them the most architecturally sound prescription option.
• •Z-drug risks are underestimated: Ambien accounts for nearly 90% of z-drug prescriptions and over 40% of all sleep medication prescriptions in the US, yet chronic use disrupts sleep architecture, induces anterograde amnesia, and carries dependence risks comparable to benzodiazepines. The FDA's 2019 black box warning covers documented cases of driving, eating, and self-injury with no subsequent memory.
• •Trazodone for long-term use: Prescribed off-label at 50–100mg, trazodone is one of the few sleep medications that actively increases slow-wave N3 sleep rather than suppressing it. It inhibits 5-HT2, histamine H1, and alpha-1 adrenergic receptors, is inexpensive, non-controlled, and produces less morning hangover than most alternatives, making it a practical longer-term option alongside DORAs.
• •Melatonin dosing and timing: The evidence-based dose for shortening sleep latency is 4mg, taken one to three hours before bed — not the 5–10mg doses commonly sold. Higher doses disrupt circadian alignment rather than support it. Melatonin functions as a circadian timing signal, not a sedative, so it works for jet lag and shift work but provides minimal benefit for general insomnia.